Alnylam Pharmaceuticals, INC 8-K filings

Alnylam Pharmaceuticals reported strong Q2 2026 results with significant revenue growth, but revised its full-year TTR net product revenue guidance downwards.

Alnylam Pharmaceuticals announced first quarter 2026 financial results, achieving over $1 billion in quarterly product revenues for the first time, driven by significant growth in TTR therapies.

Alnylam Pharmaceuticals' Board of Directors has granted CEO Yvonne Greenstreet a special performance-based equity award to incentivize future growth and leadership through 2029.

Alnylam Pharmaceuticals reported robust fourth quarter and full year 2025 financial results, achieving GAAP and non-GAAP profitability driven by significant AMVUTTRA sales and outlining ambitious 2026 pipeline goals.

Alnylam Pharmaceuticals announced its ambitious Alnylam 2030 strategy, alongside preliminary full-year 2025 net product revenues of $2,987 million and robust 2026 revenue guidance.

Alnylam Pharmaceuticals announced a partial repurchase of its 1.00% Convertible Senior Notes due 2027 for approximately $51.9 million in cash.

Alnylam Pharmaceuticals announced changes to its Board of Directors, with two long-serving members departing and a new independent director appointed.

Alnylam Pharmaceuticals reported strong third-quarter 2025 financial results, driven by significant growth in its TTR franchise, leading to an upward revision of its full-year revenue guidance.

Alnylam Pharmaceuticals, Inc. has entered into a new $500 million revolving credit facility to support working capital and general corporate purposes.

Alnylam Pharmaceuticals successfully completed a $661.25 million offering of 0.00% Convertible Senior Notes due 2028 and concurrently repurchased $637.8 million of its existing 2027 convertible notes.

Alnylam Pharmaceuticals announced the pricing of an upsized $575 million zero-coupon convertible senior notes offering due 2028, alongside a significant repurchase of existing 2027 notes.

Alnylam Pharmaceuticals announced robust second-quarter 2025 financial results, driven by significant growth in AMVUTTRA sales, leading to an upward revision of its full-year revenue guidance.

Alnylam Pharmaceuticals announced a strategic reorganization of its Research and Development functions, appointing Pushkal Garg, M.D., as Executive Vice President, Chief Research and Development Officer, and expanding Kevin Fitzgerald, Ph.D.'s responsibilities, aiming to accelerate pipeline progress and achieve its 2030 RNAi therapeutics delivery goal.

Alnylam Pharmaceuticals held its 2025 Annual Meeting of Stockholders, approving a charter amendment to allow for officer exculpation and re-electing directors.

Alnylam Pharmaceuticals announces a successful first quarter in 2025, marked by a 28% year-over-year increase in global net product revenues, driven by the strong performance of AMVUTTRA and key regulatory approvals.

Alnylam's AMVUTTRA (vutrisiran) gains FDA approval for treating cardiomyopathy in adults with transthyretin-mediated amyloidosis (ATTR-CM), reducing cardiovascular mortality and hospitalizations.

Alnylam Pharmaceuticals announces the retirement of Dr. Phillip A. Sharp from its Board of Directors, effective May 8, 2025, while he will continue to serve on the Scientific Advisory Board.

Alnylam Pharmaceuticals announces a successful 2024 with significant revenue growth and provides optimistic financial guidance for 2025, including expected profitability.

Alnylam reports a 33% increase in 2024 product revenue and anticipates achieving non-GAAP profitability in 2025.

Alnylam Pharmaceuticals announced a 34% year-over-year increase in global net product revenues for Q3 2024, driven by its TTR business, and submitted regulatory applications for AMVUTTRA in the U.S. and EU.

Alnylam Pharmaceuticals announced a 34% year-over-year increase in global net product revenues for Q2 2024, driven by its TTR business, and positive topline results from the HELIOS-B Phase 3 study of vutrisiran.

Alnylam Pharmaceuticals successfully held its 2024 Annual Meeting, re-electing four Class II directors and ratifying PricewaterhouseCoopers LLP as its independent auditor.

Alnylam Pharmaceuticals announced a 32% year-over-year increase in global net product revenues for the first quarter of 2024, alongside advancements in their clinical pipeline.

Alnylam Pharmaceuticals has formalized a separation agreement with its former Chief Legal Officer, Indrani L. Franchini, including severance, benefits continuation, and a consulting arrangement.

Alnylam Pharmaceuticals announced robust 2023 financial results, highlighted by a 39% increase in global net product revenues, and provided a positive outlook for 2024.

Alnylam Pharmaceuticals' Executive Vice President, Chief Legal Officer, and Secretary, Indrani L. Franchini, will transition from her role effective March 1, 2024.